Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 19, 2024
- Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to the Alpha DaRT® for patients with recurrent glioblastoma multiforme (GBM) -
Read more at globenewswire.com4.04
-0.16 (-3.81%)
NASDAQ:DRTSW (10/22/2025, 4:30:01 PM)
0.349
+0 (+1.22%)
Find more stocks in the Stock Screener
